These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31792991)

  • 1. Subtype-Dependent Reporting of Stroke With SGLT2 Inhibitors: Implications From a Japanese Pharmacovigilance Study.
    Sato K; Mano T; Iwata A; Toda T
    J Clin Pharmacol; 2020 May; 60(5):629-635. PubMed ID: 31792991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system.
    Zhang L; Pan C; Yang X; Jiang D; Cao M
    Expert Opin Drug Saf; 2024 Jun; 23(6):785-792. PubMed ID: 37203199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study.
    Chen G; Li X; Cui Q; Zhou Y; Zhao B; Mei D; Xuemei
    Int Urol Nephrol; 2022 Nov; 54(11):2949-2957. PubMed ID: 35579781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose cotransporter-2 inhibitors and abnormal serum potassium: a real-world, pharmacovigilance study.
    Yu M; Zhao S; Fan X; Lv Y; Xiang L; Li R
    J Cardiovasc Med (Hagerstown); 2024 Aug; 25(8):613-622. PubMed ID: 38949149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study.
    Goldman A; Fishman B; Twig G; Raschi E; Cukierman-Yaffe T; Moshkovits Y; Pomerantz A; Ben-Zvi I; Dankner R; Maor E
    Cardiovasc Diabetol; 2023 Jan; 22(1):16. PubMed ID: 36694178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
    Sato K; Mano T; Iwata A; Toda T
    J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports.
    Palapra H; Viswam SK; Kalaiselvan V; Undela K
    Int J Clin Pharm; 2022 Dec; 44(6):1425-1433. PubMed ID: 36224513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database.
    García M; Arteche-Martinez U; Lertxundi U; Aguirre C
    J Clin Pharmacol; 2021 Feb; 61(2):187-192. PubMed ID: 32827151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stress cardiomyopathy (Takotsubo syndrome) in patients who received adrenergic agonist drugs: A pharmacovigilance study using the Japanese Adverse Drug Event Report (JADER) database.
    Sato K; Iwata A; Kurihara M; Mano T; Toda T
    J Cardiol; 2022 Jan; 79(1):36-41. PubMed ID: 34493421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlations Between SGLT-2 Inhibitors and Acute Renal Failure by Signal Detection Using FAERS: Stratified Analysis for Reporting Country and Concomitant Drugs.
    Katsuhara Y; Ikeda S
    Clin Drug Investig; 2021 Mar; 41(3):235-243. PubMed ID: 33564981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter-2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis.
    Mascolo A; Rafaniello C; di Mauro G; Ruggiero D; Campitiello MR; Donniacuo M; Berrino PM; Rossi F; Paolisso G; Capuano A
    Front Pharmacol; 2023; 14():1245642. PubMed ID: 38027019
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacovigilance Assessment of Drug-Induced Acute Pancreatitis Using a Spontaneous Reporting Database.
    Niinomi I; Hosohata K; Oyama S; Inada A; Wakabayashi T; Iwanaga K
    Int J Toxicol; 2019; 38(6):487-492. PubMed ID: 31470743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach.
    Hosohata K; Inada A; Oyama S; Furushima D; Yamada H; Iwanaga K
    J Clin Pharm Ther; 2019 Feb; 44(1):49-53. PubMed ID: 30014591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS.
    Zhou X; Ye X; Guo X; Liu D; Xu J; Hu F; Zhai Y; Gao Y; Xu X; Dong Z; He J
    Front Pharmacol; 2021; 12():766125. PubMed ID: 34987394
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
    Pariente A; Gregoire F; Fourrier-Reglat A; Haramburu F; Moore N
    Drug Saf; 2007; 30(10):891-8. PubMed ID: 17867726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Adverse Event Profiles of Tumor Necrosis Factor-Alfa Inhibitors: Analysis of a Spontaneous Reporting Database.
    Wakabayashi T; Hosohata K; Oyama S; Inada A; Ueno S; Kambara H; Iida T; Nakatsuji T; Uchida M; Iwanaga K
    Ther Clin Risk Manag; 2020; 16():741-747. PubMed ID: 32884275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
    Sato K; Mano T; Iwata A; Toda T
    Biosci Trends; 2020 May; 14(2):139-143. PubMed ID: 32321905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database.
    Perlman A; Heyman SN; Matok I; Stokar J; Muszkat M; Szalat A
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1108-1113. PubMed ID: 29174031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.